Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

June 3, 2015

Primary Completion Date

December 21, 2025

Study Completion Date

December 21, 2025

Conditions
Constitutional Mismatch Repair Deficiency SyndromeLynch SyndromeMalignant GliomaRecurrent Brain NeoplasmRecurrent Childhood EpendymomaRecurrent Diffuse Intrinsic Pontine GliomaRecurrent MedulloblastomaRefractory Brain NeoplasmRefractory Diffuse Intrinsic Pontine GliomaRefractory EpendymomaRefractory Medulloblastoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo CSF and blood sample collection

PROCEDURE

Conventional Magnetic Resonance Imaging

Undergo standard MRI

PROCEDURE

Diffusion Tensor Imaging

Undergo DTI

PROCEDURE

Diffusion Weighted Imaging

Undergo MR diffusion imaging

PROCEDURE

Dynamic Contrast-enhanced MR Perfusion

Undergo DCE permeability MRI

PROCEDURE

Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging

Undergo DSC perfusion MRI

PROCEDURE

Magnetic Resonance Spectroscopic Imaging

Undergo MR spectroscopy

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

30329

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta

38105

Saint Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

Lurie Children's Hospital-Chicago, Chicago

77030

Texas Children's Hospital, Houston

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH